Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$9.26B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  ABIO
ARCA biopharma
ABIO
60 / 100
Penny Stock
$3.45arrow_drop_up1.47%$0.05

Performance History

Stocklytics logo
Key Stats
Open$3.26
Prev. Close$3.25
EPS-0.37
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap46548532.00
PE Ratio-
LOWHIGH
Day Range3.21
3.42
52 Week Range1.56
3.88
Ratios
P/B Ratio1.27
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %46.21%
EBITDA Margin %-
ROE %-13.57%
EPS-0.37

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

60vs 54. Market Avg.

All Score 60 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

ABIOMARKET
Value5339
Quality4340
Ownership3017
Growth6146
Dividends-38
check_circle

ARCA biopharma 's Price discount from all time high of 100% is great compared to market average of 43.16%. This indicates ABIO could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$726.31
24H (%)arrow_drop_down2.63%
24H ($)-$19.64
MARKET CAP$690.55B
PRICE$501.13
24H (%)arrow_drop_up1.61%
24H ($)$7.95
MARKET CAP$462.00B
PRICE$147.91
24H (%)arrow_drop_up1.48%
24H ($)$2.17
MARKET CAP$356.43B
PRICE$125.78
24H (%)arrow_drop_up0.43%
24H ($)$0.55
MARKET CAP$318.60B

About ARCA biopharma (ABIO)

ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Michael R. Bristow M.D., Ph.D.
Headquarters
Westminster
Employees
5
Exchange
NASDAQ
add ARCA biopharma  to watchlist

Keep an eye on ARCA biopharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the 52-week high and low for ARCA biopharma (ABIO)?

For ARCA biopharma (ABIO), the 52-week high is $3.88, which is 14.12% from the current price. The 52-week low is $1.56, the current price is 117.95% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
What is ARCA biopharma 's (ABIO) price per share?

The current price per share for ARCA biopharma (ABIO) is $3.4. The stock has seen a price change of $0.15 recently, indicating a 4.62% change. This reflects the stock's recent market performance and investor sentiment.

help
Is ARCA biopharma (ABIO) a growth stock?

ARCA biopharma (ABIO) has shown an average price growth of 8.6% over the past three years. It has received a score of 71 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ARCA biopharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is ARCA biopharma (ABIO) stock price performance year to date (YTD)?

As of the latest data, ARCA biopharma (ABIO) has a year-to-date price change of 102.62%. Over the past month, the stock has experienced a price change of 92.09%. Over the last three months, the change has been 111.18%. Over the past six months, the figure is 71.72%.

help
Is ARCA biopharma (ABIO) a profitable company?

ARCA biopharma (ABIO) has a net income of -$5.34M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$7.3M. Furthermore, the EBITDA is -$7.12M.

help
What is the market capitalization of ARCA biopharma (ABIO)?

ARCA biopharma (ABIO) has a market capitalization of $46.55M. The average daily trading volume is 355.99K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.